Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Peroxitech Therapeutics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Peroxitech Therapeutics

    Menu

    Peroxitech Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Peroxitech Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Peroxitech Announces Closing of $25M Series A Financing to Develop Novel Treatment for Acute Lung Injury

              Details:

              Peroxitech’s lead product, PIP-2 is delivered into the lungs to prevent the cytokine storm cascade to treat and prevent ALI. PIP-2 helps to target cytokine build up in the lungs that leads to respiratory failure with hypoxemia and tissue acidosis, regardless of etiology.

              Lead Product(s): PIP-2

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PIP-2

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Perceptive Xontogeny Venture Fund

              Deal Size: $25.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing December 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Peroxitech Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Peroxitech Therapeutics Secures Seed Financing to Advance New Treatment of Acute Lung Injury

              Details:

              Peroxitech’s lead product, PIP-2 is delivered into the lungs to prevent the cytokine storm cascade to treat and prevent ALI. PIP-2 helps to target cytokine build up in the lungs that leads to respiratory failure with hypoxemia and tissue acidosis, regardless of etiology.

              Lead Product(s): PIP-2

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PIP-2

              Highest Development Status: Preclinical Product Type: Peptide

              Partner/Sponsor/Collaborator: Xontogeny, LLC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing May 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY